KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Current Deferred Revenue data on record, last reported at $553.0 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 11.9% year-over-year to $553.0 million; the TTM value through Dec 2025 reached $553.0 million, down 11.9%, while the annual FY2025 figure was $553.0 million, 11.9% down from the prior year.
  • Current Deferred Revenue reached $553.0 million in Q4 2025 per REGN's latest filing, up from $545.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $627.7 million in Q4 2024 and bottomed at $381.1 million in Q2 2023.
  • Average Current Deferred Revenue over 5 years is $516.7 million, with a median of $516.7 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: plummeted 32.7% in 2023, then surged 53.77% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $507.8 million in 2021, then dropped by 5.89% to $477.9 million in 2022, then fell by 3.98% to $458.9 million in 2023, then surged by 36.78% to $627.7 million in 2024, then fell by 11.9% to $553.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $553.0 million in Q4 2025, $545.6 million in Q3 2025, and $481.9 million in Q2 2025.